Table 2.
Univariate analysis for relapse risk, DFS, and OS
| Characteristics | Relapse | DFS | OS | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Age (15–40 vs > 40years) | 0.572 (0.143–2.295) | 0.431 | 1.271 (0.548–2.949) | 0.576 | 1.308 (0.564–3.032) | 0.532 |
| Gender (male vs female) | 0.798 (0.214–2.974) | 0.737 | 0.816 (0.352–1.889) | 0.634 | 0.831 (0.359–1.924) | 0.665 |
| Risk classification at diagnosis (intermediate risk vs high risk) | 0.596 (0.149–2.383) | 0.464 | 0.996 (0.43–2.305) | 0.992 | 0.993 (0.429–2.3) | 0.988 |
| HLA matched (10/10 matched vs 9/10 matched) | 2.547 (0.318–20.375) | 0.378 | 1.099 (0.405–2.979) | 0.853 | 1.077 (0.397–2.921) | 0.884 |
| Median interval from diagnosis to HSCT (< 12 vs ≥ 12 months) | 0.637 (0.159–2.549) | 0.524 | 0.866 (0.339–2.215) | 0.764 | 0.855 (0.334–2.186) | 0.743 |
| BM blasts at transplantation (< 20 vs ≥ 20%) | 1.163 (0.242–5.602) | 0.85 | 1.065 (0.393–2.889) | 0.901 | 1.108 (0.409–3.005) | 0.84 |
| Conditioning regimen (BFCT vs BCAT) | 0.411 (0.103–1.645) | 0.209 | 0.622 (0.265–1.455) | 0.273 | 0.59 (0.252–1.381) | 0.224 |
| aGvHD of grades II–IV (with vs without) | 5.185 (0.648–41.495) | 0.121 | 0.701 (0.304–1.617) | 0.404 | 0.664 (0.288–1.533) | 0.338 |
| cGvHD (with vs without) | 11.838 (1.416–98.95) | 0.023 | 4.067 (1.421–11.641) | 0.009 | 4.145 (1.452–11.838) | 0.008 |
| Severe cGvHD (with vs without) | 0.551 (0.114–2.66) | 0.458 | 1.169 (0.267–5.114) | 0.836 | 1.183 (0.27–5.177) | 0.823 |
| CMV viremia (with vs without) | 11.905 (1.483–95.55) | 0.02 | 1.452 (0.628–3.359) | 0.383 | 1.401 (0.607–3.246) | 0.428 |